HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Adjuvant therapy of lung cancer].

Abstract
The authors evaluated in a retrospective investigation the effectiveness of adjuvant postoperative chemotherapy (ChT) and radiotherapy (RT), as compared with surgery alone, according to morphological types and stages of cancer lung (CaP). In a group of 321 patients 143 were treated by operation alone, 36 by operation and RT and 53 by operation and ChT. ChT involved administration of Cyclophosphamide, 30 mg/kg, at three-week intervals, some of the patients were also given vincaalkaloids. Therapy was repeated after 6-month intervals. According to the gross mortality data the probability of survival (PP) was compared by Kaplan-Meier's method. Improved PP was proved in patients with small cell lung cancer (MbCa) treated by operation and ChT and in third-stage disease treated by adjuvant ChT. In stage I of CaP adjuvant ChT and RT cause deterioration of the perspective of survival, as compared with operation alone and in stage II adjuvant ChT and RT are no advantage. The authors recommend adjuvant ChT in patients with surgically treated small-cell carcinoma and in stage III of operated CaP. They draw attention to the different response of tumours to adjuvant ChT and RT according to types and stages of CaP, to the fact that RT does not prolong the survival and to the possibility of preoperative ChT and RT in some types and stages of CaP.
AuthorsM Pesek, L Kohoutková, E Kotorová, F Sefrna
JournalCasopis lekaru ceskych (Cas Lek Cesk) Vol. 129 Issue 6 Pg. 179-83 (Feb 09 1990) ISSN: 0008-7335 [Print] Czech Republic
Vernacular TitleAdjuvantní lécba rakoviny plic.
PMID2331735 (Publication Type: English Abstract, Journal Article)
Topics
  • Combined Modality Therapy
  • Female
  • Humans
  • Lung Neoplasms (therapy)
  • Male
  • Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: